| BackgroundChronic for hepatitis B is our common chronic epidemic and infection is one of the most common type of chronic HBV. The world health organization report, the global about 2 billion people were infected through HBV and, including 350 million people for chronic hbv infected. The mechanism of HBV is a complex problem, so far has not fully expounded. Antiviral is the mainly treatment to cure chronic HBV infection of Western medicine, to clean or a reproduction, thereby inhibit HBV reduce or terminate the liver disease or inflammations, necrosis fiber, to prevent disease and cirrhosis for lost liver work or liver failure, and the cancer. Current applications and is clinically clinical studies in resisting for hepatitis B virus into IFN, nucleoside antibiotics and non-ribosomal. However, the serious side effects of IFN lead to the nature, nucleoside antibiotics incidence of drug with the application for increase in drug therapy changes after difficulty, the n non-ribosomal kind of antiviral drugs research is at an elementary stage to present a factor for the pure Western medicine cannot thoroughly eliminate or could be replicated permanent HBV. The chinese medicine to treat liver has a long history, success has not only to adjust the body's immune functions, and there was no role of the virus. With hepatitis B chronic disease in our country, china's medical standards and china's economic problem, from there to study with respect to treat chronic for hepatitis B, especially for 1 XULN 0.05), then the treatment group at 3 months after the HBeAg seroconversion rate was significantly higher (P<0.05), the second two after treatment The rate of HBeAg negative group had improved, but still the treatment group most obvious difference between the two groups was statistically more significant than before (P<0.05).ConclusionMedicine (kidney disinfection side) combined with Lamivudine can improve the 1×ULN |
PDF Full Text Request